Genelux (GNLX)
Develops Olvi-Vec, an oncolytic virus therapy for platinum-resistant ovarian cancer.
Something off on this page? Send us feedback.
The clinical-stage pipeline centers on Olvi-Vec, a proprietary modified vaccinia-virus candidate designed to kill tumor cells and stimulate immune responses to tumor neoantigens. Its key program is the U.S. OnPrime registrational trial in platinum-resistant or refractory ovarian cancer.
Built from Loma Linda University research, the clinical-stage pipeline of oncolytic viral immunotherapies centers on Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified vaccinia-virus candidate. It is intended to selectively kill tumor cells and stimulate immune responses to each patient's tumor neoantigens.
Olvi-Vec is being evaluated in OnPrime/GOG-3076, a multicenter, randomized, open-label registrational trial for platinum-resistant or refractory ovarian cancer in the United States. The intended product model is an off-the-shelf personalized immunotherapy: one virus product is administered to different patients, with the expected immune response directed to each patient's tumor neoantigens.
Clinical execution of OnPrime is the material operating dependency.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Oct 21, 2025 | Maxim Group | Target | Target: — | Target: $20 |
| Oct 21, 2025 | Lake Street | Target | Target: — | Target: $16 |
| Oct 21, 2025 | Loop Capital Markets | Target | Target: — | Target: $16 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $18.7M · Total debt $2.4M · Total assets $26.2M · Shareholders' equity $16.1M
- Revenue
- $0
- Operating income
- −$9.6M
- Net income
- −$9.5M
No dividends on record.
| Institutions | 21.76% | 9.84M shares | |
|---|---|---|---|
| 73 holders · as of Jun 30, 2026 | |||
| Insiders | 14.23% | 6.44M shares | |
| 13 holders · as of Sep 2, 2026 | |||
| Strategic holders | 14.86% | 6.72M shares | |
| 2 holders · as of Nov 14, 2025 | |||
| Other | 49.15% | 22.24M shares | |
| remainder | |||
45.25M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Armistice Capital, LLCStrategic | 9.33% | 4.22M | filed Nov 14, 2025 |
Aladar Szalay1Insider10 percent owner | 6.93% | 3.13M | filed Feb 17, 2026 |
Highbridge Capital Management, LLCStrategic | 5.53% | 2.50M | filed Oct 25, 2024 |
Woodward Diversified Capital, LLCInstitution | 5.00% | 2.26M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 3.71% | 1.68M | as of Jun 30, 2026 |
- Aladar Szalay's transaction reports restate only vehicles that traded; the 2026 ownership statement (3.13M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Yong Yu | officer: Chief Scientific Officer | −9,683 | $2.75 |
| Aug 31, 2026 | Thomas Zindrick | officer: President and CEO | −34,463 | $2.67 |
| Aug 31, 2026 | Joseph Cappello | officer: Chief Technical Officer | −10,257 | $2.74 |
| Aug 4, 2026 | Thomas Zindrick | officer: President and CEO | −3,023 | $2.95 |
| Aug 4, 2026 | Joseph Cappello | officer: Chief Technical Officer | −653 | $2.95 |
- Oncolytics Biotech
Intravenous dsRNA immunotherapy for gastrointestinal tumors
- Replimune Group
HSV-1 oncolytic immunotherapy for solid tumors
- Candel Therapeutics
Adenovirus and HSV immunotherapies for solid tumors
- CG Oncology
Intravesical oncolytic immunotherapy for bladder cancer
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Genelux | $2.52 | −3.64% | $117.0M | — | — | 14,629.2 | −98.2% |
| Oncolytics Biotech | $0.6742 | −5.48% | $71.6M | — | — | — | — |
| Replimune Group | $12.75 | −5.38% | $1.13B | — | — | — | — |
| Candel Therapeutics | $11.58 | −2.28% | $868.3M | — | — | — | — |
| CG Oncology | $73.49 | −5.47% | $6.86B | — | — | 1,101.0 | — |
| Median | — | — | 1,101.0 | — |